EpicentRx
- Biotech or pharma, therapeutic R&D
With NDA submissions planned for 2027, EpicentRx’s clinical stage programs, RRx-001 and ADAPT-001, represent novel approaches that target cancer vulnerabilities and improve quality of life:
- RRx-001 (Nibrozetone): A Phase 2b/3, FDA Fast Track-designated, first-in-class small molecule that inhibits the NLRP3-inflammasome to protect normal tissues from chemotherapy, radiation, and other inflammatory-driven side effects and diseases. The anti-inflammatory mechanism has also been heavily studied in preclinical neurodegenerative disease models, backed by the Michael J Fox Foundation, FightMND, and CDMRP.
- ADAPT-001: A TGF-β targeting immunotherapy designed to reverse immune suppression and enhance checkpoint inhibitor response—especially in refractory tumors. Compelling clinical results were featured by oral presentation at ASCO ’24, with several CPI-refractory patients seeing prolonged responses after introducing AdAPT-001 with a previously failed checkpoint inhibitor.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}